Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment by using the patient's own T-cells to target tumors.

In the current study, published today in the journal Nature Biotechnology, Cheng and his colleagues created an exosome system ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ineffective ...

CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...

Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target ...

Please provide your email address to receive an email when new articles are posted on . Current therapies do not prevent the onset of new lesions within a field of cancerization. Immune checkpoint ...

Simple blood markers may predict nivolumab outcomes in metastatic renal cell carcinoma. Learn how eosinophils could help ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...